Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
38.84 USD | -0.59% | -1.65% | +50.87% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 73.27 and 10.26 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 5.94 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+50.87% | 1.05B | - | ||
+19.36% | 80.64B | A | ||
+15.93% | 9.07B | A- | ||
+42.06% | 4.68B | - | ||
-22.01% | 4.53B | A- | ||
+8.28% | 4.06B | B- | ||
-26.61% | 2.21B | C- | ||
+11.22% | 2.19B | B | ||
+11.64% | 2B | - | - | |
-42.69% | 1.82B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CALTX Stock
- CALT Stock
- Ratings Calliditas Therapeutics AB